When we talk about cannabis and how it works, we usually refer to compounds such as THC, CBD or terpenes. Fortunately, hemp is a more complex plant that contains a huge range of ingredients that are valuable for our health. Today we will discuss the topic of cannabichrome and cannabigerol.
Cannabichromene, or CBC, is a non-psychoactive cannabinoid found in cannabis, it is also one of the naturally occurring phytocannabinoids that carries a number of potential positive therapeutic properties. It has antimicrobial, anti-inflammatory, analgesic and neurogenesis-stimulating properties. It is found in younger cannabis plants, albeit in small amounts.
CBG, or cannabigerol, is one of the phytocannabinoids and, like CBC, has no psychoactive properties. It is one of the first cannabinoids produced by young plants, hence its term "cannabis stem cell". CBG is known for its antidepressant, antipsychotic and bone growth stimulating properties.
A new series of tests in Israel has shown that both CBC and CBG exhibit anti-cancer properties on cancer cells.
Tests have shown that the cannabinoids CBC (Cannabichromene) and CBG (Cannabigerol) exhibit anti-cancer properties when tested on human gastrointestinal cancer cells. The research was conducted by Cannabics Pharmaceuticals at the High Through-Put Screening (HTS) facility in Israel.
The research used the HTS screening platform and examined the effects of various cannabinoids on human gastrointestinal cancer cells, in addition to other types of cancer previously tested.
Both CBC and CBG have been shown in studies to induce significantly higher rates of necrosis in these cancer cells compared to other cannabinoids.
The head of cannabidiol research company Dr. Yaakov Waksman said: "My working assumption is that these results show that there may be a correlation between cannabinoid's topological polar surface area (TPSA) value and its ability to induce anticancer activity, reducing cancer rates. cell viability. Both CBC and CBG, as neutral cannabinoids, have been found to have a TPSA value that allows the cannabinoid molecule to penetrate the cancer cell membrane, while their acidic form (CBCA and CBGA) do not. This may explain the difference in anticancer activity rates shown. '
“Gastrointestinal cancer is one of the leading and most widespread causes of cancer death worldwide. We are intrigued by the results we obtained in the laboratory, and our goal is to consider the emphasis on this organ system and further investigate the diverse anticancer properties of cannabinoids. We believe these preliminary results confirm our vision; which aims to personalize cannabinoid-based cancer treatment. "Said study co-founder Dr. Eyal Ballan.
"Cannabics Pharmaceuticals Study Shows Cannabinoids CBC and CBG Exhibit Anti-Tumor Properties on Gastrointestinal Cancer Cells" https://www.prnewswire.com/news-releases/cannabics-pharmaceuticals-study-shows-cannabinoids-cbc-and-cbg-exhibit -300993435.html
"A pre-clinical study examined the in vitro anti-tumor effects of Cannabigerol (CBG) on human cancer cell lines" https://finance.yahoo.com/news/cannabics-pharmaceuticals-announces-cannabigerol-cbg-140000885.html
